Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon Licenses LNA to Phoenix BioTechnologies

NEW YORK, May 20 - Exiqon has non-exclusively licensed its Locked Nucleic Acids technology to Phoenix BioTechnologies, of Huntsville, Ala.

 

Under the agreement, Phoenix BioTechnologies will acquires the "recipe" for making LNA, and has the has the rights to manufacture and sell LNA oligonucleotides to the research market. The companies did not disclose the financial terms of the agreement.

 

LNA is LNA is a proprietary nucleic acid analog, which is incorporated in synthetic DNA oligos to enhance sensitivity in genomics products.

 

Exiqon, of Copenhagen, has also licensed this technology to DNAPrint of Sarasota, and Eurogentec of Sart-Tilman, Belgium.

 

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.